Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.

Harrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, Ahmed Z, Fisher A, Meftah S, Murray TK, Ottersen OP, Nagelhus EA, O'Neill MJ, Wells JA, Lythgoe MF. · 2020

Read Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. by Harrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, Ahmed Z, Fisher A, Meftah S, Murray TK, Ottersen OP, Nagelhus EA, O'Neill MJ, Wells JA, Lythgoe MF. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7447521.txt.

Introduction

Harrison and co-authors study brain waste clearance in a mouse model of Alzheimer's disease. The glymphatic system flushes waste, including tau protein, from the brain. Failed clearance may let tau build up and drive disease.

In the mouse model, glymphatic function varied by brain region. That pattern matched where tau gathered, region by region. The team then targeted aquaporin-4, a water channel key to glymphatic flow. Changing flow through this channel changed how fast tau cleared. Stronger clearance meant less tau buildup in the model. The results tie weak clearance to tau spread in this model. They also mark glymphatic flow, and aquaporin-4 in particular, as a possible treatment target for tau diseases.

Catalog record

CREATORHarrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, Ahmed Z, Fisher A, Meftah S, Murray TK, Ottersen OP, Nagelhus EA, O'Neill MJ, Wells JA, Lythgoe MF.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7447521

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model By Ian F Harrison, Ozama Ismail, Asif Machhada, Niall Colgan, Yolanda Ohene, Payam Nahavandi, Zeshan Ahmed, Alice Fisher, Soraya Meftah, Tracey K Murray, Ole P Ottersen, Erlend A Nagelhus Published in: Brain DOI: 10.1093/brain/awaa179 ABSTRACT Harrison et al. show that regional variation in glymphatic function dictates tau accumulation in a mouse model of Alzheimer’s disease tauopathy. Modifying glymphatic flow by pharmacologically targeting aquaporin-4 alters tau clearance, suggesting therapeutic potential against tauopathies. INTRODUCTION Impaired brain clearance mechanisms that result in the accumulation of aberrant proteins that define Alzheimer’s disease, provide new diagnostic and therapeutic opportunity to delay or prevent clinical symptoms. One such pathway for parenchymal protein clearance, the glymphatic system, has recently been described (Jessen et al., 2015). Its involvement in Alzheimer’s disease, however, is yet to be fully defined. Alzheimer’s disease is a devastating condition, neuropathologically characterized by the extracellular accumulation of amyloid-β in the form of plaques, and intracellular accumulation of hyperphosphorylated microtubule associated protein tau in the form of neurofibrillary tangles (NFTs). Blood–brain barrier clearance, intra- and extracellular degradation, interstitial fluid (ISF) bulk flow clearance and CSF absorption pathways have all been implicated in removal of parenchymal amyloid-β (Zlokovic et al., 2000; Glabe, 2001; Weller et al., 2008; Iliff et al., 2012; Hawkes et al., 2014), while tau is thought to be predominantly cleared by degradation, ISF bulk flow, and CSF absorption clearance mechanisms (Chesser et al., 2013; Iliff et al., 2014). Recent evidence, however, has suggested that the glymphatic system may contribute to a larger portion of parenchymal clearance of these protein species than previously thought (Iliff et al., 2012; Kress et al., 2014; Tarasoff-Conway et al., 2015). The glymphatic clearance pathway was so named for its appropriation of the lymphatic function of interstitial protein management, and its dependence upon glial water transport (Jessen et al., 2015). Hence, it describes the exchange of para-arterial CSF with ISF in the parenchymal extracellular space, and para-venous clearance out of the brain (Iliff et al., 2012; Xie et al., 2013; Holter et al., 2017). Exchange of CSF with ISF is thought to be facilitated by the expression of aquaporin 4 (AQP4) channels on astrocytic endfeet; animals lacking AQP4 exhibit a ∼70% reduction in CSF influx and a ∼55% reduction in parenchymal solute clearance (Iliff et al., 2012; Mestre et al., 2018). Furthermore, deletion of AQP4 in APP/PS1 mice has been shown to potentiate the development of amyloid-β pathology and memory deficits (Xu et al., 2015), suggesting that supressed glymphatic clearance is capable of inducing and/or advancing Alzheimer’s disease pathology. It has also been shown that the appropriate expression pattern of AQP4 polarization to astrocytic endfeet is required for efficient glymphatic CSF-ISF exchange (Iliff et al., 2014; Kress et al., 2014; Hadjihambi et al., 2019), and that this polarization in the brain declines with age (Kress et al., 2014; Zeppenfeld et al., 2016), the greatest risk factor for developing Alzheimer’s disease (Guerreiro and Bras, 2015). Moreover, it was shown recently that AQP4 polarization itself is associated with Alzheimer’s disease status (Zeppenfeld et al., 2016), suggesting that impaired glymphatic clearance may play a role in rendering the ageing brain vulnerable to aberrant protein deposition. Previous studies of glymphatic clearance in mouse models of Alzheimer’s disease however have focused largely on amyloid-β pathology (Peng et al., 2016). In human Alzheimer’s disease though, it is the tau burden, not amyloid-β load, that predicts both brain atrophy as well as cognitive status in patients with Alzheimer’s disease (Giannakopoulos et al., 2003). Furthermore, emerging evidence suggests that the extracellular space, which is cleared by the glymphatic system, acts as a conduit for neuron-to-neuron propagation and regional progression of Alzheimer’s disease tau pathology (Chesser et al., 2013; Ahmed et al., 2014; Medina and Avila, 2014; Lewis and Dickson, 2016; Wu et al., 2016). This raises the intriguing possibility that reduced glymphatic clearance of tau may potentiate disease progression via exacerbated neuron-to-neuron propagation of tangle susceptible tau protein, and as such, would be a powerful target for therapy. Here we study the glymphatic system using MRI, the clearance of parenchymal tau using intracerebral injections and CSF sampling, and the modulation of AQP4 function, in a mouse model that develops tau NFT pathology (Ramsden et al., 2005) similar to that seen in neurodegenerative diseases such as Alzheimer’s disease (Braak and Braak, 1995). By using contrast-enhanced MRI, we provide a spatial and temporal description of the glymphatic system in the mouse brain, highlighting the heterogeneous nature of glymphatic inflow in the cortex, alluding to the critical role of this clearance system in the deposition of tau protein in the brain. We assess the function of glymphatic clearance in rTg4510 mice and their ability to clear parenchymal tau protein, as well as the expression pattern of AQP4 in affected regions. Finally, we demonstrate the critical role of this water channel, by pharmacologically inhibiting its function, and assessing the impact of such an inhibition on CSF-ISF exchange and tau clearance. In this study we provide the first demonstration of impaired glymphatic function in an animal model of tauopathy and establish the essential role of AQP4 in the clearance of tau protein from the brain. MATERIALS AND METHODS Animals and drugs Generation of homozygous rTg4510 transgenic mice has been described previously (Ramsden et al., 2005). The rTg4510 and litter matched wild-type mice were licensed from the Mayo Clinic (Jacksonville, Florida, USA), bred for Eli Lilly by Taconic, and imported into the UK for study at UCL’s Centre for Advanced Biomedical Imaging. For TGN-020 experiments, C57BL/6 mice were used, imported from Charles River. For additional TGN-020 experiments, where stated, AQP4 knockout mice, generation of which has been described previously (Thrane et al., 2011) (henceforth referred to as Aqp4−/− mice) were used, imported directly from University of Oslo, Norway, into the UK for study at UCL’s Centre for Advanced Biomedical Imaging. In all other experiments, unless stated otherwise, female mice of 8.5 months of age were used. Animals were housed in groups of three to five in individually ventilated cages with ad libitum access to standard mouse chow pellets, drinking water, and environmental enrichment, on a 12-h light/dark cycle. All animal work was performed in accordance with the UK’s Animals (Scientific Procedures) Act of 1986 and was previously approved by UCL’s internal Animal Welfare and Ethical Review Body. For pharmacological inhibition of AQP4, TGN-020 (N-1,3,4-thiadiazol-2-yl-3-pyridinecarboxamide) (Tocris Bioscience) was used (Huber et al., 2009). To increase solubility, TGN-020 was dissolved in a cyclodextrin derivative, 20% w/v Captisol® (CyDex Pharmaceuticals) in water for injection. For TGN-020 experiments, mice were treated intraperitoneally with either TGN-020 (250 mg/kg in 20 ml/kg body weight) or vehicle (empty 20% Captisol®, 20 ml/kg). Tau immunohistochemistry Immunohistochemistry was performed in order to quantify cortical deposition of tau in young rTg4510 mice. Female rTg4510 mice from 3.2 to 4.7 months of age were examined. Mice were perfused with PBS before removing and hemisecting the brain. The right hemisphere was drop fixed in 10% buffered formalin before being processed using the Tissue TEK VIP processor (GMI Inc) and embedded in paraffin wax. Sections (6 μm) of the brain in the sagittal plane were collected using a rotary microtome and mounted on glass

Read the complete text